



Improving life from the inside out

Nuvios Inc.
300 Technology Square
5th Floor
Cambridge, MA 02139
(617) 551-4700
(617) 551-4701 Fax
www.nuvios.com

FOR IMMEDIATE RELEASE

CONTACT:

Bart Henderson
Chief Business Officer
Nuvios, Inc.
(617) 551-4702
bhenderson@nuvios.com

NUVIOS NAMES C. RICHARD LYTTLE PRESIDENT AND CEO

—Former Wyeth VP of Discovery for Women’s Health—

CAMBRIDGE, Mass., October 4, 2004— Nuvios, Inc. today announced the appointment of C. Richard Lyttle, PhD, as President and Chief Executive Officer. Dr. Lyttle was most recently Vice President of Discovery for Women’s Health and Bone at Wyeth, where he also served as Head of the Women’s Health Research Institute.

Nuvios is a pharmaceutical company focusing on developing a new class of drugs that build back lost bone in people with osteoporosis and other related metabolic diseases. Osteoporosis affects a significant and growing number of men and women with severe health consequences. Ten to 20 percent of people over the age of 50 die within one year of a hip fracture. And half of those who enter a nursing home as a result of a fracture never return to living on their own. Nuvios is pioneering the development of a new class of drugs that build bone, which is based on recent discoveries around the biology of nongenotropic cellular pathways that control the development and survival of bone-building osteoblasts. The company will also apply its discovery paradigm in nongenotropic signaling to other areas such as menopause, asthma, diabetes, and psoriasis.

“Nuvios is an outstanding company in one of the most compelling areas of women’s health,” said Dr. Lyttle. “With a growing population of patients, and a limited set of treatment and prevention options, osteoporosis requires a breakthrough approach to build new bone without increasing the risks of cancer and cardiovascular disease. I am excited to be a part of what promises to become a real force in the field through the development of groundbreaking new drugs for osteoporosis.”

Prior to joining Nuvios, Dr. Lyttle directed drug discovery in women’s health at Wyeth in the areas of menopause, contraception, reproductive disorders, osteoarthritis, osteoporosis, and urinary incontinence. Under his leadership, Wyeth advanced 17 new product candidates into preclinical

(MORE...)

and clinical development, including the SERM, bazedoxifene, currently in Phase III clinical trials; Tanaproget, a novel non-steroidal contraceptive; and DVS-233 for vasomotor symptoms associated with menopause. Prior to joining Wyeth, Dr. Lyttle was Professor of Obstetrics & Gynecology, and Pharmacology at the University of Pennsylvania. He received a PhD in Biochemistry from Queen's University, Kingston, Ontario, followed by postdoctoral research at the Population Council at the Rockefeller University and at the Ben May Laboratory for Cancer Research at the University of Chicago.

“Richard Lyttle is ideally suited to lead Nuvios’ efforts to commercialize a new generation of drug therapies for treating and preventing osteoporosis and related metabolic diseases,” said Christopher K. Mirabelli, PhD, a Director of Nuvios and General Partner of HealthCare Ventures. “Rich is a recognized leader in women’s health and metabolic disease, and in his 25-year career, he has produced an impressive record of successful drug development results. Rich established and grew the Women’s Health Research Institute at Wyeth to more than 130 scientists and jump-started the industry’s most productive discovery and development efforts in the field. We look forward to continuing to build a truly great company guided by his leadership and vision.”

ABOUT NUVIOS

Nuvios is a leader in the discovery and development of a new generation of drug therapies for treating and preventing osteoporosis and metabolic bone diseases. The company’s primary focus is on discoveries related to the growth of osteoblasts and osteoclasts, which enable the formation of bone with high specificity. Nuvios is a privately held biotechnology company located in Cambridge, Massachusetts. The company raised \$24 million in its first institutional financing in 2003. Investors include HealthCare Ventures, MPM Capital, and Oxford Bioscience Partners. www.nuvios.com

###